NCT06089369View on ClinicalTrials.gov

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

November 30, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sintilimab (9 cycles)

IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 9 cycles）

DRUG

Sintilimab (18 cycles)

IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles）

OTHER

Active surveillance

Active surveillance

Trial Locations (1)

430030

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Tongji Hospital

OTHER